Eicosapentanoic Acid
Hyperlipidemia
Barbara Jakše s.p.N/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Hyperlipidemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lipitor Poznan University of Medical Sciences | Phase 4 | BBB |
Rosuvastatin Nanjing First Hospital, Nanjing Medical University | Phase 4 | BBB |
PRAVASTATIN University of North Carolina, Chapel Hill | Phase 4 | BBB |
Ezetimibe NewAmsterdam Pharma | Phase 4 | BBB |
Darunavir University of Colorado, Denver | Phase 4 | BB |
View all 32 →
Same molecule, other indications
Eicosapentanoic Acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →